



































CD22 (Siglec–2)はシグレックファミリーに属し，N–グリカン上のα2–6 sialyl lactosamineや
O–グリカン上のシアリルTn抗原に結合することが報告されている10）．また，CD22はB細胞に





4つはITIM (Immunoreceptor tyrosine-based inhibition motif) に位置する11）．ITIM相同性領域の
































































































































参 考 文 献
1）Kim, Y.J. and Varki, A. (1997). Perspectives on the significance of altered glycosylation of glycoproteins
in cancer. Glycoconj J., 14: 569–76.
2） Bhaumik, M., Harris, T., Sundaram, S., Johnson, L., Guttenplan, J., Rogler, C., Stanley, P. (1998)
158 ムチンをリガンドとする免疫抑制情報のシグナル伝達機構
Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine
on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression. Cancer Res.
58: 2881–7.
3）Dennis, J.W. (1992). Changes in glycosylation associated with malignant transformation and tumor pro-
gression. In Cell surface carbohydrates and cell development (ed. Fukuda, M.), pp.161–194.
4）Kim, Y.S., Gum, J. and Brockhausen, I. (1996). Mucin glycoproteins in neoplasia. Glycoconj J., 13:
693–707.
5） Taylor-Papadimitriou, J. and Finn, O.J. (1997). Biology, biochemistry and immunology of carcinoma-asso-
ciated mucins. Immunol. Today 18: 105–107.
6）Kobayashi, H., Terao, T. and Kawashima, Y. (1992). Serum sialyl Tn as an independent predictor of poor
prognosis in patients with epithelial ovarian cancer. J Clin . Oncol., 10: 95–101.
7）Nakamori, S., Kameyama, M., Inaoka, S., Furukawa, H., Ishikawa, O., Sasaki, Y., Kabuto, T., Iwanaga, T.,
Matsushita, Y. and Irimura, T. (1993). Increased expression of sialyl Lewis X antigen correlates with poor
survival in patients with colorectal carcinoma : clinicopathological and immunohistochemical study.
Cancer Res., 52: 3632–3637.
8） Fung, P.Y.S. and Longenecker, B.M. (1991). Specific immunosuppressive activity of epiglycanin, a mucin-
like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res., 51: 1170–1176.
9） Crocker, P.R. and Varki, A. (2001). Siglecs, sialic acids and innate immunity. TRENDS in Immunology,
28: 337–342.
10）Brinkman, E.C.M. and Varki, A. (2000). New aspects of siglec binding specificites, including the signifi-
cance of fucosylation and of the sialyl-Tn epitope. J. Biol. Chem., 275: 8625–8632.
11）Tedder, T. F., Tuscano, J., Sato, S. and Kehrl, J.H. (1997). CD22 a B lymphocyte-specific adhesion mole-
cule that regulates antigen receptor signaling. Annu. Rev. Immunol., 15: 481–504.
12）Stamenkovic, I., Sgroi, D., Aruffo, A., Sy, M.S. and Anderson, T. (1991). The B lymphocyte adhesion mol-
ecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase,
CD75, on B cells. Cell, 66: 1133–44.
13）Hanasaki, K., Powell, L.D. and Varki, A. (1995). Binding of human plasma sialoglycoproteins by the B
cell-specific lectin CD22. Selective recognition of immunoglobulin M and haptoglobin. J. Biol. Chem.,
270: 7543–50.
14）Cambier, J.C., Pleiman, C.M., Clark, M.R. (1994). Signal transduction by the B cell antigen receptor and
its coreceptors. Annu Rev Immunol. 12: 457–86.
15）Dorken, B., Moldenhauer, G., Pezzutto, A., Schwartz, R., Feller, A., Kiesel, S., Nadler, L.M. (1986). HD39
(B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated
human B lymphocytes. J Immunol. 136: 4470–9.
16）Kamoshida, S. and Tsutsumi, Y. (1998). Expression of MUC-1 glycoprotein in plasma cells, follicular den-
dritic cells, myofibroblasts and perineurial cells: Immunohistochemical analysis using three monoclonal
antibodies. Pathol. Int. 48: 776–785.
17）MacLennan, I.C.M. (1994). Germinal centers. Annu Rev Immunol. 12: 117–39.
戸　田　宗　豊・中　田　　　博 159
